Navigation Links
CEL-SCI Corporation Releases Letter to Shareholders

VIENNA, Va., Dec. 12 /PRNewswire-FirstCall/ -- The following letter is being released by CEL-SCI CORPORATION (NYSE Alternext US: CVM) to its shareholders:

Dear Fellow Shareholders:

Recently we have had two pieces of important news for CEL-SCI Corporation and its shareholders. First, the U.N. World Health Organization's Agency for Research on Cancer report, in reference to the "cancer burden" wrote that "the global burden doubled in the last 30 years of the 20th Century, and it is estimated that this will double again between 2000 and 2020 and nearly triple by 2030". Cancer will soon become the Number One killer in the world, ahead of heart disease. Those increases are much greater than many people had expected and clearly make our non-toxic Multikine cancer product even more important to develop. Second, we need your help with a legislative proposal advocated by the Biotechnology Industry Organization (BIO) which would help CEL-SCI bring Multikine to market faster. Last, what percentage of people do you think will get cancer and how many of them will die from it? The answer may shake you (see below).

    In this letter I also want to review the general status of our Multikine cancer drug:

        1. In the last few months we have hit major milestones.  We signed a
           Multikine licensing agreement with Teva Pharmaceuticals, a
           multinational pharmaceutical company, which will participate in
           and pay for part of our Phase III trial, we took delivery of our
           new manufacturing facility in Baltimore (see the pictures at
  and click on Updated Pictures of Manufacturing
           Facility), and we extended our existing Multikine partnership with
           Orient Europharma (OEP) of Taiwan to cover a larger territory.
           OEP, like Teva, will participate in and pay for part of the Phase
           III clinical trial.  We also presented very promising results on a
           newly discovered rheumatoid arthritis vaccine.

        2. Cancer, our main target for Multikine, is quickly becoming the
           number one killer, surpassing heart disease.  Cancer treatment is
           not a discretionary expenditure and therefore pharmaceutical
           companies and investors alike are attracted to cancer therapies.

        3. Many pharmaceutical companies are making cancer research a
           priority.  This is a change from their prior focus on life style,
           mass marketed drugs.  After the Vioxx debacle and other issues
           discovered later, it has become significantly more difficult to
           receive FDA approval for life style drugs.  Recently Eli Lilly
           purchased the cancer company Imclone for $6.5 billion, Pfizer
           announced that it would focus on cancer and biologics (Multikine is
           a biologic for the treatment of cancer) and Roche is trying to
           purchase the half of the cancer company Genentech that it does not
           own for about $45 billion.

        4. As a late stage Phase III cancer company focusing on a large unmet
           medical need, we believe that CEL-SCI is well positioned to partner
           Multikine with other companies and thereby pay for future
           development costs.

        5. The reason we believe that Multikine is an attractive cancer
           therapy is because we have shown very good clinical data:

           a. 12% of patients receiving Multikine have no tumor left before
              the normal treatment has even started,

           b. overall the Multikine treated patients have 50% less tumor cells
              before the normal treatment has even started, and

           c. long-term survival improvement was 33%, all without Multikine
              induced toxicity.

    We believe that Multikine is able to achieve these excellent results for three reasons:

           a. Multikine is the first immunotherapy drug to be used before the
              immune system is destroyed by radiation and chemotherapy. Up to
              now other immunotherapy drugs have been given after radiation
              and chemotherapy, a time when the immune system is severely

           b. Multikine is also able to circumvent the tumor's defense
              mechanisms by creating a new and different attack through CD-4
              cells instead of the usual CD-8 cells which the tumor has
              learned to shut down.

           c. Multikine renders the remaining tumor cells susceptible to the
              effect of the follow-on radiation and chemotherapy, thereby
              potentially increasing the effectiveness of these treatments.

        6. Only one pivotal Phase III trial is needed to get to approval from
           the FDA and if approved, Multikine would become the first line
           standard of care in head and neck cancer, a multi-billion market.

Now let me share with you a staggering statistic. In a June 5, 2007 interview in the Wall Street Journal Genentech's CEO, Dr. Arthur Levinson, stated that that "42% of everybody out there is going to get cancer. And half of those 42% are going to die of cancer." That means that almost every 1 in 2 persons will get cancer. I have devoted my life to finding a new and better way of treating cancer, but I had no idea that the number was going to be that big. The effects on patients and their families from cancer are devastating. We must try to do better!

With that in mind I want to highlight a very recent effort by The Biotechnology Industry Organization (BIO) to help American biotechnology companies get through the current financial crisis. BIO is lobbying Congress to include tax provisions in fiscal stimulus legislation to help small, capital-intensive companies, such as CEL-SCI. The name of the proposal is "One Time Refund of NOLs in Lieu of Other Tax Benefits to Sustain Critical R&D During Financial Distress". The proposal is not a hand-out. It calls for Congress to allow small companies to "temporarily elect to receive a refund of their accumulated net operating losses (NOLs) at a discounted rate in lieu of claiming qualified research expenses." The plan, which applies only to tax year 2008, requires that refunds be reinvested in U.S. - based research. Refund recipients would permanently forgo the ability to claim all NOLs involved in the computation of the refund. This plan would really help CEL-SCI and might allow us to launch our very important Phase III clinical trial much faster. I ask you to please contact your Congressperson and Senator to express support for this

proposal. This is very important to everyone's life because, unfortunately, I do not know of any family that has escaped the devastating effects of cancer. Congresspersons and Senators listen to you, their constituents. I have already written to my own representatives.

Please write to your representatives right away and make a personal difference in the fight against cancer. Please tell them that you support the "One Time Refund of NOLs in Lieu of Other Tax Benefits to Sustain Critical R&D During Financial Distress" proposed by the Biotechnology Industry Organization (BIO). This is a critical bill and it needs your lobbying to become reality.

The internet address for contacting your Congressperson is:

The internet address for contacting your Senators is:

We thank you for your support.


Geert Kersten

Chief Executive Officer

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended September 30, 2007. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

SOURCE CEL-SCI Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CEL-SCI to Present at the Noble Financial Conference
2. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
3. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
4. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
5. CEL-SCI Takes Delivery of New Manufacturing Facility
6. Updated Pictures of CEL-SCI Manufacturing Facility Available Online
7. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. BioElectronics Corporation Announces Singapore and Malaysia Sales
Post Your Comments:
(Date:10/11/2017)... , ... October 11, 2017 , ... ... gene in its endogenous context, enabling overexpression experiments and avoiding the use of ... small RNA guides is transformative for performing systematic gain-of-function studies. , This ...
(Date:10/11/2017)... BioMarketing, a leading provider of patient support solutions, has announced ... network, which will launch this week. The VMS CNEs will ... to enhance the patient care experience by delivering peer-to-peer education ... professionals to help women who have been diagnosed and are ... ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer ... treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and bind ...
(Date:10/10/2017)... ... 10, 2017 , ... Dr. Bob Harman, founder and CEO of VetStem ... The event entitled “Stem Cells and Their Regenerative Powers,” was held ... Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief ...
Breaking Biology Technology:
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...
(Date:3/30/2017)... 2017  On April 6-7, 2017, will host ... hackathon at Microsoft,s headquarters in Redmond, ... on developing health and wellness apps that provide a ... Genome is the first hackathon for personal genomics ... companies in the genomics, tech and health industries are ...
Breaking Biology News(10 mins):